Driving the Cell and Gene Therapy Industry Forward
We’re building the future of medicine by combining two essential capabilities: gene editing technologies and the expertise to manufacture complex therapies at scale. Through partnerships with biopharma companies, we provide the tools, facilities, and knowledge needed to develop genetic medicines faster and more efficiently, accelerating their delivery to patients worldwide.

Powering Cell and Gene Therapy Companies with Integrated Manufacturing and Technologies
cGMP Manufacturing, Process Development and Analytical Development Services
ElevateBio BaseCamp® is our cGMP manufacturing business, designed to deliver genetic medicines from concept through commercialization.
Gene Editing Technologies and R&D
ElevateBio Life Edit is our gene editing technologies and R&D business, featuring one of the world’s largest gene editing toolboxes, opening a new frontier of medicine.
Realizing the Potential of Your Programs from Concept to Cure
Through BaseCamp and Life Edit, we deliver unparalleled expertise, capabilities, quality, and high-touch customer service. We have integrated a differentiated set of platform technologies, including full-spectrum gene editing, with industry-leading manufacturing expertise to develop genetic medicines faster and more efficiently, ultimately accelerating their delivery to patients.

Press Releases
Publications
// February 4, 2025 | Cell & Gene
Accelerating Innovative Cell Therapy Development Through Phase-Appropriate Potency Control
Deb Bhattacharya, Ph.D. and Cindy Riggins, Ph.D.
// May 23, 2024 | Cell and Gene Therapy
Outsourced Pharma Capacity Update May 2024
Debaditya Bhattacharya, Ph.D. VP, Analytical Development and Miranda Williams Scientist I, Analytical Development discuss BaseCamp’s analytical capabilities and more in a recorded webcast.
// February 28, 2023 | The Long Run
A Life in Biotech & the Cell Therapy Wave: David Hallal on The Long Run
This episode was recorded in person at the JP Morgan Healthcare Conference in San Francisco. Biotech history buffs will especially enjoy the first half, where he talks about what pharmaceutical sales was like and what it was like to work at Amgen in the early days.
// October 12, 2022 | Biotech 2050 Podcast
A New Vision for Cell and Gene Therapy, Andrew Sandford & Michael Paglia, ElevateBio BaseCamp
Andrew Sandford and Michael Paglia are the President and COO, respectively, of ElevateBio BaseCamp, a cell and gene therapy technology company powering transformative therapies. They join us from the company’s manufacturing facilities in Waltham, Massachusetts, for a discussion about the landscape of company creation in the cell and gene therapy space and how ElevateBio is helping companies bring innovation and therapeutics to clinics and patients to help treat and cure diseases.
// July 12, 2022 | Ori Spotlight
Mike Paglia – Chief Operating Officer, ElevateBio
Mike Paglia, COO BaseCamp, on ‘Ori Spotlight’ podcast discussing how Elevate supports the cell and gene therapy industry, the long-term benefits of digital manufacturing processes, and the importance of removing the cost barrier to CGTs.
// March 22, 2022 | Accelerating Clinical Podcast
The Power of Collective Wisdom
Amit Mathur, CIO ElevateBio, on ‘Accelerating Clinical’ podcast, discussing the power of collective wisdom
// February 22, 2022 | Cell & Gene Therapy Insights
Banking on the future of regenerative medicine with cGMP-compliant iPSC lines
Melissa Carpenter, pHD, CSO Regenerative Medicine
// January 18, 2022 | American Builders Quarterly
Mario Miele Begins with the End in Mind
Mario Miele, VP Facilities and Engineering, article discussing the buildout of BaseCamp
Elevated Insights

// May 2025
LETI-101: Life Edit’s Novel Gene Editing Approach to Huntington’s Disease Treatment
By Amy Pooler, Ph.D., SVP, Research and Development of Life Edit

// Apr 2025
ElevateBio’s Next-Generation Sequencing Core: Meeting the Challenges of Cost, Time and Data Quality with Expertise and Collaboration
By Adriana Geldart, Ph.D., Senior Director, Next-Generation Sequencing, ElevateBio

// Apr 2025
Partner Case Study: Accelerating Gene Editing Manufacturing
By ElevateBio and Beam Therapeutics

// Feb 2025
Accelerating Innovative Cell Therapy Development Through Phase-Appropriate Potency Control
By Deb Bhattacharya, Ph.D., and Cindy Riggins, Ph.D., ElevateBio

// Sep 2024
Introducing ElevateBio’s Emerging Technology Lab
By Mercedes Segura, PhD, VP, Process Development, ElevateBio BaseCamp

// Sep 2024
How Life Edit is using AI to expand the therapeutic boundaries of CRISPR
By Shaorong (Ron) Chong, Ph.D., VP of Technology Development, and Joel Parker, Ph.D., VP of Computational Biology, Life Edit Therapeutics

// Aug 2024
The complexities of tomorrow’s cell therapies: The future is gene editing
By Mitch Finer, Ph.D., Co-Founder of ElevateBio, former Chief Executive Officer of Life Edit Therapeutics, and Current Strategic Advisor to ElevateBio and Life Edit

// Jul 2024
The Future of Manufacturing and Medicine Rising in Pittsburgh’s Hazelwood Green
By Mario Miele, SVP, Facilities and Engineering, ElevateBio

// Jun 2024
How ElevateBio’s Foundry Model is Changing the Future of Genetic Medicines
By David Hallal, Chairman and CEO, ElevateBio

// Nov 2023
A new chapter in gene editing: The diversity, versatility, and coolness of Life Edit’s technologies
By Hui-Chia Yu-Kemp and Drew Kelso, Technology Development Scientists, Life Edit Therapeutics, an ElevateBio company

// Oct 2023
Biotechnology: The Key to America’s Next Manufacturing Revolution
By Heidi Wagner, Global Head of Government Affairs, and Mike Paglia, Chief Operating Officer of ElevateBio BaseCamp

// Aug 2023
Partner Case Study: Accelerating Treg Therapy Manufacturing
By ElevateBio and Abata Therapeutics

// Nov 2022
The Medicines of Tomorrow: A primer on the gene editing landscape
By Adrian Oliver, Ph.D., Senior Scientist of Technology Development, Life Edit Therapeutics

// Nov 2022
Right from the start: Successfully managing the life cycles of cell and gene therapies
By Mike Paglia, Chief Operating Officer ElevateBio BaseCamp

// Nov 2022
ElevateBio’s Lentiviral Vector Platform: Right the first time
By: Mercedes Segura, Vice President, Process Development, ElevateBio, Dawn Maier, Vice President, Emerging Technologies, ElevateBio, and Bojiao Yin, Director of Vector Process Development, ElevateBio

// Nov 2022
Addressing Gaps in Cystic Fibrosis Treatment by Fixing Nonsense Mutations
By Alexandra Crawley, PH.D., Co-founder and Principal Investigator, Life Edit Therapeutics, Inc.

Team of Industry-Leading Experts
We have assembled a leading team of experts with first-hand experience in the discovery, development, and manufacturing of cell and gene therapies. Driven by a common mission to power life-changing therapies, the team works to advance discoveries and development at a speed the world demands.
Partner with ElevateBio®
Wherever you are in your product lifecycle, we can strengthen and accelerate the development of your transformative therapies with our enabling technologies and unmatched manufacturing capabilities.
// Work with us
